跳轉至內容
Merck
全部照片(1)

重要文件

1453005

USP

纳洛酮盐酸盐二水合物

United States Pharmacopeia (USP) Reference Standard

同義詞:

(5α)-4,5-Epoxy-3,14-dihydroxy-17-(2-propen-1-yl)morphinan-6-one

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C19H21NO4
CAS號碼:
分子量::
327.37
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

naloxone

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

InChI 密鑰

UZHSEJADLWPNLE-GRGSLBFTSA-N

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Naloxone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Naloxone Hydrochloride
  • Naloxone Hydrochloride Injection
  • Pentazocine and Naloxone Tablets
  • Buprenorphine and Naloxone Sublingual Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Nina Eriksen et al.
International journal of stroke : official journal of the International Stroke Society, 9(6), 802-810 (2012-08-30)
Strokes have both ischemic and hemorrhagic components, but most studies of experimental stroke only address the ischemic component. This is likely because investigations of hemorrhagic transformation are hindered by the lack of methods based on unbiased principles for volume estimation.
Marco Lanza et al.
British journal of pharmacology, 171(15), 3693-3701 (2014-04-25)
CR4056 is a novel imidazoline-2 (I2 ) ligand exhibiting potent analgesic activity in animal models of pain. In this study, we investigated the effects of CR4056 in a well-established model of postoperative pain where rats develop hyperalgesia in the injured
Daisuke Yamada et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(8), 1852-1860 (2014-02-13)
Although the underlying mechanism remains unknown, several studies have suggested benefits of n-3 long-chain polyunsaturated fatty acid (PUFA) for patients with anxiety disorders. Elevated fear is thought to contribute to the pathogenesis of particular anxiety disorders. The aim of the
Prabhat Singh et al.
Psychopharmacology, 232(2), 465-475 (2014-07-26)
Opiate exposure for longer duration develops state of dependence in humans and animals, which is revealed by signs and symptoms of withdrawal precipitated by opioid receptor antagonists. The sudden withdrawal of opioids produces a withdrawal syndrome in opioid-dependent subjects. Insulin
Ana M Torres-Guzman et al.
Arthritis research & therapy, 16(2), R64-R64 (2014-03-13)
Clinical and preclinical studies have shown that supplementation with ω-3 polyunsaturated fatty acids (ω-3 PUFAs) reduce joint destruction and inflammation present in rheumatoid arthritis (RA). However, the effects of individual ω-3 PUFAs on chronic arthritic pain have not been evaluated

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務